Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biotech layoffs
Biotech
Cycle Pharma scoops up beleaguered rare disease biotech
Cycle has extended a tender offer to buy all outstanding shares of Applied common stock for 8.8 cents per share at closing.
Gabrielle Masson
Dec 12, 2025 9:55am
Fierce Biotech Layoff Tracker 2025: Geron, Pfizer & more
Dec 11, 2025 10:00am
Valneva closes site to consolidate R&D footprint, lays off 30
Nov 26, 2025 12:57pm
Nurix trims staff as trial for lead BTK degrader kicks off
Nov 21, 2025 5:05am
Genetic medicines biotech halves team
Nov 20, 2025 10:15am
Nxera lays off staff, pivots pipeline in profitability push
Nov 17, 2025 9:44am
